Results of a multicenter phase II trial for older patients with c-Kit positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C (LDAC) and imatinib.

被引：1

作者：

Heidel, F

Cortes, J

Ruecker, F

Kaufmann, M

Aulitzky, W

Letvak, L

Kindler, T

Huber, C

Dohner, H

Kantarjian, H

Fischer, T

机构：

[1] Univ Hosp Mainz, Mainz, Germany

[2] Univ Hosp Ulm, Ulm, Germany

[3] Robert Bosch Krankenhaus, Stuttgart, Germany

[4] Novartis Pharm Corp, E Hanover, NJ USA

[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

BLOOD | 2005年 / 106卷 / 11期

关键词：

D O I：

10.1182/blood.V106.11.1853.1853

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1853

引用

页码：527A / 527A

页数：1

共 50 条

[1] Results of a multicenter phase II trial for older patients with c-kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose ara-C and imatinib
Heidel, Florian
Cortes, Jorge
Ruecker, Frank G.
Aulitzky, Walter
Letvak, Laurie
Kindler, Thomas
Huber, Christoph
Doehner, Hartmut
Kantarjian, Hagop
Fischer, Thomas
CANCER, 2007, 109 (05) : 907 - 914
[2] Phase I evaluation of tipifarnib in combination with low-dose Ara-C (LDAC) in high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): Interim results
Cortes, J. E.
Feldman, E. J.
Douer, D.
Raza, A.
Fruchtman, S.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[3] Phase I evaluation of tipifarnib in combination with low dose Ara-C (LDAC) in high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): final results
Feldman, E. J.
Douer, D.
Walsh, W.
Moyo, V. M.
Cortes, J. E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[4] Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia
Dennis, Mike
Russell, Nigel
Hills, Robert K.
Hemmaway, Claire
Panoskaltsis, Nicki
McMullin, Mary-Frances
Kjeldsen, Lars
Dignum, Helen
Thomas, Ian F.
Clark, Richard E.
Milligan, Don
Burnett, Alan K.
BLOOD, 2015, 125 (19) : 2923 - 2932
[5] Phase II study of omacetaxine (OM) and low-dose AraC (LDAC) in older patients with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Kadia, Tapan M.
Jabbour, Elias
Pemmaraju, Naveen
Faderl, Stefan
Borthakur, Gautam
Thomas, Deborah A.
Daver, Naval Guastad
Ravandi, Farhad
Kantarjian, Hagop
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[6] LOW-DOSE CYTARABINE (ARA-C) IN THE TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) AND ACUTE MYELOID-LEUKEMIA (AML)
MUFTI, GJ
OSCIER, DG
HAMBLIN, TJ
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 61 (03) : 571 - 571
[7] Arsenic trioxide (ATO) is safe and effective in combination with low-dose ara-C (LDAC) for the treatment of IPSS-2 myelodysplastic syndrome (MDS) and poor-prognosis acute myeloid leukemia (AML) in elderly patients
Roboz, GJ
Ritchie, EK
Allen-Bard, S
Curcio, TJ
Provenzano, JL
Samuel, MS
Schuster, MW
Bloch, AW
Feldman, EJ
BLOOD, 2005, 106 (11) : 786A - 786A
[8] Phase II Trial Of Cladribine and Low-Dose AraC (LDAC) Alternating With Decitabine In Older Patients With Acute Myeloid Leukemia (AML)
Kadia, Tapan M.
Borthakur, Gautam
Ferrajoli, Alessandra
Jain, Preetesh
Jabbour, Elias
Verstovsek, Srdan
Pemmaraju, Naveen
Faderl, Stefan
Ravandi, Farhad
Konopleva, Marina
Tuttle, Carla
Brandt, Mark
Wang, Xuemei
Garcia-Manero, Guillermo
Kantarjian, Hagop M.
Cortes, Jorge E.
BLOOD, 2013, 122 (21)
[9] Mylotarg, fludarabine, ara-C and cyclosporine (MFAC) in patients with newly diagnosed acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
Tsimberidou, AM
Estey, E
Cortes, J
Thomas, D
Garcia-Manero, G
Faderl, S
Verstovsek, S
O'Brien, S
Kantarjian, H
Giles, F
BLOOD, 2002, 100 (11) : 339A - 339A
[10] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Cortes, J
Plunkett, WK
Estey, EH
Keating, MJ
Madden, T
Sampath, D
Faderl, S
Beran, M
Dancey, J
Kantarjian, HM
BLOOD, 2001, 98 (11) : 211B - 211B

← 1 2 3 4 5 →